<DOC>
	<DOCNO>NCT02127905</DOCNO>
	<brief_summary>The protocol design compassionate treatment patient Fanconi Anemia HLA-matched sibling donor . The purpose study determine likelihood engraftment Fanconi Anemia patient use total body irradiation ( TBI ) , cyclophosphamide ( CY ) , fludarabine ( FLU ) antithymocyte globulin ( ATG ) follow unrelated donor hematopoietic cell transplant T-cell depletion use CliniMACS device .</brief_summary>
	<brief_title>Unrelated HSCT Patients With Fanconi Anemia</brief_title>
	<detailed_description>The major obstacle successful alternate donor HCT patient Fanconi Anemia graft failure . While T-cell depletion decrease incidence aGVHD , effect improve long term survival unproven . To potentially improve engraftment rate , choose relatively new immunosuppressive agent , fludarabine ( FLU ) , FLU antineoplastic agent show effective immunosuppressive agen BMT conditioning therapy . The addition FLU commonly use preparative regimen CY TBU Fanconi Anemia patient may improve engraftment rate . Based present data outcome , hematopoietic stem cell transplantation use total body irradiation ( 450 cGy ) , cyclophosphamide ( 10 mg/kg IV ) fludarabine ( 35 mg/m2 IV ) preparative cytoreductive therapy become standard treatment hematologic manifestation Fanconi Anemia CHLA . However , use Isolex 300i replace CliniMACS process T-cell depletion . The CliniMACS CD34 Reagent System investigational medical device yet approve FDA . This device use vitro select enrich specific cell population . When use CliniMACS CD34 Reagent , system selects CD34+ cell heterogenous hematological cell population transplantation case clinically indicate . Based gathered data , CliniMACS contribute factor toxicity patient , although may potential elicit `` antibody '' reaction patient , process significant life-saving benefit compare potential risk .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<criteria>Patients must &gt; 2 month &lt; 21 year age diagnosis Fanconi anemia . Patients must HLAA , B , DRB1 identical 1 antigen mismatch relate ( nonsibling ) unrelated donor . Patients donor type HLAA B use serological molecular technique DRB1 use high resolution molecular typing . ( Patients 2 antigen mismatch related donor eligible protocol evaluate separately ) . Patients FA must high risk genotype aplastic anemia ( AA ) myelodysplastic syndrome without excess blast . Aplastic anemia define least one following : 1. platelet count &lt; 20 x 109/L 2 . ANC &lt; 5 x 108/L 3 . Hgb &lt; 8 g/dL least one following : 1. transfusion dependence 2. supportive care toxicity Myelodysplastic syndrome multilineage dysplasia without chromosomal anomaly . High risk genotype ( e.g . IVS4 exon 14 FANCC mutation ) Adequate major organ function include : Cardiac : ejection fraction &gt; 45 % Renal : creatinine clearance &gt; 40 mL/min . Hepatic : clinical evidence hepatic failure ( e.g . coagulopathy , ascites ) Karnofsky performance status &gt; 70 % Lansky &gt; 50 % Women child bear age must use adequate birth control negative pregnancy test . Available HLAgenotypically identical relate donor . The harvested marrow ( prior TCD ) contain minimum 2.5 x 108 nucleated cells/kg recipient body weight goal &gt; 5.0 x 108 nucleated cells/kg recipient body weight . Positive lymphocytotoxic crossmatch donor ( T cell B cell ) History gram negative sepsis systemic fungal infection ( proven suspect base radiographic study ) . Myelodysplastic syndrome excess blast leukemia . Active CNS leukemia time HCT . Malignant solid tumor ( e.g . squamous cell carcinoma head/neck/cervix ) within 2 year HCT . Pregnant lactate female . Prior radiation therapy prevent use TBI 450 cGy .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fanconi Anemia</keyword>
	<keyword>compassionate treatment</keyword>
	<keyword>BMT</keyword>
	<keyword>HSCT</keyword>
	<keyword>unrelated</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>PBSC</keyword>
	<keyword>peripheral blood</keyword>
	<keyword>CD34+</keyword>
</DOC>